Nintedanib Stada (Nintedanib)

Nintedanib inhibits several receptor tyrosine kinases, including VEGFR, FGFR and PDGFR. By blocking these signals it reduces fibroblast proliferation, angiogenesis and the formation of scar tissue, which underlies its antifibrotic and antitumor effects.

The dose of Nintedanib Stada is determined by the prescribing clinician based on the specific indication, patient characteristics and tolerability. The prescribing information provides guidance, but the exact regimen should be individualized and not assumed.

Data on Nintedanib use in pregnancy or lactation are limited. Because potential risks to the fetus or infant cannot be excluded, the drug is generally avoided unless the potential benefit justifies the potential risk. Consultation with a specialist is essential.

To request Nintedanib Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for fibrotic lung disease is pirfenidone, another antifibrotic agent. While both aim to slow disease progression, Nintedanib targets a broader range of tyrosine kinases, which may provide additional anti‑angiogenic activity in certain cancers. Safety profiles differ, with Nintedanib more frequently causing gastrointestinal upset and liver enzyme changes.

Nintedanib Stada should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Nintedanib is taken orally, usually as a tablet swallowed whole with water. It is generally recommended to take the medication with food to lessen gastrointestinal discomfort, but patients should follow the specific instructions provided by their healthcare professional.

The most serious adverse events include significant liver injury (hepatotoxicity), increased risk of bleeding, and rare severe infections. Patients should be monitored regularly for liver function abnormalities, signs of bleeding, and any unexpected infections, and should report these promptly to their physician.

Nintedanib is contraindicated in individuals with known hypersensitivity to the drug or any of its components. It should also be avoided in patients with severe liver impairment, uncontrolled bleeding disorders, or those who are pregnant unless the potential benefit outweighs the risk.